Matches in Wikidata for { <http://www.wikidata.org/entity/Q88144273> ?p ?o ?g. }
Showing items 1 to 40 of
40
with 100 items per page.
- Q88144273 description "article scientifique publié en 2014" @default.
- Q88144273 description "artículu científicu espublizáu en xunetu de 2014" @default.
- Q88144273 description "scientific article published on 07 July 2014" @default.
- Q88144273 description "wetenschappelijk artikel" @default.
- Q88144273 description "наукова стаття, опублікована в липні 2014" @default.
- Q88144273 name "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 name "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 type Item @default.
- Q88144273 label "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 label "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 prefLabel "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 prefLabel "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 P1433 Q88144273-C94A9A53-8C90-4AA7-AE4B-875EE222F87F @default.
- Q88144273 P1476 Q88144273-4ECA37DA-A4D9-4BBE-AB28-E36F9377742C @default.
- Q88144273 P2093 Q88144273-144211FB-D1B5-4951-970C-4215E45029FA @default.
- Q88144273 P2093 Q88144273-240E1B0B-93AB-495A-97A4-D40E45F40377 @default.
- Q88144273 P2093 Q88144273-3BFCB00A-599B-4E39-B66B-A75FED52D8D7 @default.
- Q88144273 P2093 Q88144273-A995BFC1-B894-4CED-AC2A-84CFA1E593CC @default.
- Q88144273 P304 Q88144273-4F76B79B-9DE1-4EE8-9530-20FB96B77241 @default.
- Q88144273 P31 Q88144273-0616CA35-7468-4243-9A12-92FAA99A82E8 @default.
- Q88144273 P356 Q88144273-CD49D070-1652-4374-816C-2468E5A1E66D @default.
- Q88144273 P433 Q88144273-F1AC0417-2FFC-48CB-81E0-0A9D3876C349 @default.
- Q88144273 P478 Q88144273-AFFD4CF3-40DB-41A0-8FDC-C77721C92B1B @default.
- Q88144273 P577 Q88144273-F7BD6933-6688-4787-A1C6-5901EBC4A5AE @default.
- Q88144273 P698 Q88144273-D08B4568-01D9-4BA5-92B0-1416861E53F4 @default.
- Q88144273 P356 03007995.2014.938150 @default.
- Q88144273 P698 24960148 @default.
- Q88144273 P1433 Q5195063 @default.
- Q88144273 P1476 "Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22" @default.
- Q88144273 P2093 "Dana L Baker" @default.
- Q88144273 P2093 "Kun Peng" @default.
- Q88144273 P2093 "Melissa Cheu" @default.
- Q88144273 P2093 "Saloumeh Kadkhodayan Fischer" @default.
- Q88144273 P304 "1927-1929" @default.
- Q88144273 P31 Q13442814 @default.
- Q88144273 P356 "10.1185/03007995.2014.938150" @default.
- Q88144273 P433 "10" @default.
- Q88144273 P478 "30" @default.
- Q88144273 P577 "2014-07-07T00:00:00Z" @default.
- Q88144273 P698 "24960148" @default.